Javascript must be enabled to continue!
Evaluation of Geographic Disparities in Cervical Cancer Survival Across Maine
View through CrossRef
Introduction. National data exists suggesting the existence of geographic disparities in oncology care within the United States. It is unknown whether geographic disparities present a problem for women with gynecologic malignancies locally in Maine.
Methods. Data for each cervical cancer case diagnosed or treated under the MaineHealth system between 2007 and 2011 were acquired from the MaineHealth Network Registry. Average annual incidence and 5-year survival were calculated for each county in Maine and were mapped using geographic information systems (GIS) software. Next, cases were divided into 2 groups: those residing less than or equal to 60 miles from the sole gynecologic oncology practice in Maine and those residing over 60 miles from the practice. 5-year survival rates of each group were compared using chi-square testing. Demographics and risk factors of the two groups were compared with the 2-sample t-test or Fisher’s exact test.
Results. The average annual incidence of cervical cancer in each county of Maine between 2007 and 2011 ranged from 0 to 0.91 new cases per 10,000 female persons. The 5-year survival rate within each county ranged from 0% to 100%. Women with cervical cancer residing less than or equal to 60 miles from the Maine-based gynecologic oncology practice had a 5-year survival rate of 63.0%, while those residing farther than 60 miles had a 5-year survival rate of 71.9% (p=0.12).
Conclusions. No significant geographic disparities in survival outcomes were found for women diagnosed with cervical cancer in Maine between 2007 and 2011.
Title: Evaluation of Geographic Disparities in Cervical Cancer Survival Across Maine
Description:
Introduction.
National data exists suggesting the existence of geographic disparities in oncology care within the United States.
It is unknown whether geographic disparities present a problem for women with gynecologic malignancies locally in Maine.
Methods.
Data for each cervical cancer case diagnosed or treated under the MaineHealth system between 2007 and 2011 were acquired from the MaineHealth Network Registry.
Average annual incidence and 5-year survival were calculated for each county in Maine and were mapped using geographic information systems (GIS) software.
Next, cases were divided into 2 groups: those residing less than or equal to 60 miles from the sole gynecologic oncology practice in Maine and those residing over 60 miles from the practice.
5-year survival rates of each group were compared using chi-square testing.
Demographics and risk factors of the two groups were compared with the 2-sample t-test or Fisher’s exact test.
Results.
The average annual incidence of cervical cancer in each county of Maine between 2007 and 2011 ranged from 0 to 0.
91 new cases per 10,000 female persons.
The 5-year survival rate within each county ranged from 0% to 100%.
Women with cervical cancer residing less than or equal to 60 miles from the Maine-based gynecologic oncology practice had a 5-year survival rate of 63.
0%, while those residing farther than 60 miles had a 5-year survival rate of 71.
9% (p=0.
12).
Conclusions.
No significant geographic disparities in survival outcomes were found for women diagnosed with cervical cancer in Maine between 2007 and 2011.
Related Results
Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis
Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis
BackgroundDespite a remarkable progress in the reduction of global rate of maternal mortality, cervical cancer has been identified as the leading cause of maternal morbidity and mo...
Uptake and determinants of cervical cancer prevention services among female college students in Kenya: A cross-sectional survey
Uptake and determinants of cervical cancer prevention services among female college students in Kenya: A cross-sectional survey
Abstract
Introduction
Cervical cancer is the leading cause of cancer death in women in low- and middle-income countries. In Ken...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Cervical Cancer or Cervical Endometriosis – Review and Case Report
Cervical Cancer or Cervical Endometriosis – Review and Case Report
According to cancer death rates for women worldwide, this form of cancer ranks fourth after breast, bronchopulmonary, and colorectal cancer, affecting around 570,000 women annually...
C/EBPβ expression decreases in cervical cancer and leads to tumorigenesis
C/EBPβ expression decreases in cervical cancer and leads to tumorigenesis
Abstract
Background
Cervical cancer is currently estimated to be the fourth most common cancer among women worldwide and the leading cause of cancer...
CERVICAL CANCER STATUS, KNOWLEDGE, ATTITUDE AND ASSOCIATED FACTORS AMONG REPRODUCTIVE AGE WOMEN RESIDING IN HARGEISA, SOMALILAND
CERVICAL CANCER STATUS, KNOWLEDGE, ATTITUDE AND ASSOCIATED FACTORS AMONG REPRODUCTIVE AGE WOMEN RESIDING IN HARGEISA, SOMALILAND
Introduction: Cervical cancer results from a Human Papilloma Virus (HPV) infection. Seventy (70%) cervical cancers and pre-cancerous cervical lesions are attributed to HPV types 16...
Abstract IA32: Con: The ACA will not eliminate disparities in cancer screening
Abstract IA32: Con: The ACA will not eliminate disparities in cancer screening
Abstract
While hopes have risen that the Affordable Care Act (ACA) will eliminate screening health disparities, we argue that disparities will persist. In this sessi...

